BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

257 related articles for article (PubMed ID: 21593597)

  • 1. CpG island hypermethylation of BRCA1 and loss of pRb as co-occurring events in basal/triple-negative breast cancer.
    Stefansson OA; Jonasson JG; Olafsdottir K; Hilmarsdottir H; Olafsdottir G; Esteller M; Johannsson OT; Eyfjord JE
    Epigenetics; 2011 May; 6(5):638-49. PubMed ID: 21593597
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Promoter Hypermethylation and Expression Changes of BRCA1 Gene in a Cohort of Sporadic Breast Cancer Cases among Pakistani Population.
    Arif T; Anwar N
    Asian Pac J Cancer Prev; 2020 Aug; 21(8):2395-2401. PubMed ID: 32856871
    [TBL] [Abstract][Full Text] [Related]  

  • 3. BRCA1 promoter hypermethylation, 53BP1 protein expression and PARP-1 activity as biomarkers of DNA repair deficit in breast cancer.
    Jacot W; Thezenas S; Senal R; Viglianti C; Laberenne AC; Lopez-Crapez E; Bibeau F; Bleuse JP; Romieu G; Lamy PJ
    BMC Cancer; 2013 Nov; 13():523. PubMed ID: 24191908
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Epigenetic Inactivation of BRCA1 Through Promoter Hypermethylation and Its Clinical Importance in Triple-Negative Breast Cancer.
    Yamashita N; Tokunaga E; Kitao H; Hitchins M; Inoue Y; Tanaka K; Hisamatsu Y; Taketani K; Akiyoshi S; Okada S; Oda Y; Saeki H; Oki E; Maehara Y
    Clin Breast Cancer; 2015 Dec; 15(6):498-504. PubMed ID: 26195437
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Promoter hypermethylation of p16, BRCA1 and RASSF1A genes in triple-negative breast cancer patients from Serbia.
    Kozomara Z; Supic G; Krivokuca A; Magic Z; Dzodic R; Milovanovic Z; Brankovic-Magic M
    J BUON; 2018; 23(3):684-691. PubMed ID: 30003738
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Constitutive expression of AhR and BRCA-1 promoter CpG hypermethylation as biomarkers of ERα-negative breast tumorigenesis.
    Romagnolo DF; Papoutsis AJ; Laukaitis C; Selmin OI
    BMC Cancer; 2015 Dec; 15():1026. PubMed ID: 26715507
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Hypermethylation of BRCA1 gene: implication for prognostic biomarker and therapeutic target in sporadic primary triple-negative breast cancer.
    Zhu X; Shan L; Wang F; Wang J; Wang F; Shen G; Liu X; Wang B; Yuan Y; Ying J; Yang H
    Breast Cancer Res Treat; 2015 Apr; 150(3):479-86. PubMed ID: 25783183
    [TBL] [Abstract][Full Text] [Related]  

  • 8. MYC overexpression and poor prognosis in sporadic breast cancer with BRCA1 deficiency.
    Ren J; Jin F; Yu Z; Zhao L; Wang L; Bai X; Zhao H; Yao W; Mi X; Wang E; Olopade OI; Wei M
    Tumour Biol; 2013 Dec; 34(6):3945-58. PubMed ID: 23860775
    [TBL] [Abstract][Full Text] [Related]  

  • 9. BRCA promoter methylation in sporadic versus BRCA germline mutation-related breast cancers.
    Vos S; Moelans CB; van Diest PJ
    Breast Cancer Res; 2017 May; 19(1):64. PubMed ID: 28569220
    [TBL] [Abstract][Full Text] [Related]  

  • 10. CpG island tumor suppressor promoter methylation in non-BRCA-associated early mammary carcinogenesis.
    Vasilatos SN; Broadwater G; Barry WT; Baker JC; Lem S; Dietze EC; Bean GR; Bryson AD; Pilie PG; Goldenberg V; Skaar D; Paisie C; Torres-Hernandez A; Grant TL; Wilke LG; Ibarra-Drendall C; Ostrander JH; D'Amato NC; Zalles C; Jirtle R; Weaver VM; Seewaldt VL
    Cancer Epidemiol Biomarkers Prev; 2009 Mar; 18(3):901-14. PubMed ID: 19258476
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Molecular features of the basal-like breast cancer subtype based on BRCA1 mutation status.
    Prat A; Cruz C; Hoadley KA; Díez O; Perou CM; Balmaña J
    Breast Cancer Res Treat; 2014 Aug; 147(1):185-91. PubMed ID: 25048467
    [TBL] [Abstract][Full Text] [Related]  

  • 12. CpG island methylation profile of estrogen receptor alpha in Iranian females with triple negative or non-triple negative breast cancer: new marker of poor prognosis.
    Ramezani F; Salami S; Omrani MD; Maleki D
    Asian Pac J Cancer Prev; 2012; 13(2):451-7. PubMed ID: 22524805
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinicopathological analysis of homologous recombination-deficient breast cancers with special reference to response to neoadjuvant paclitaxel followed by FEC.
    Imanishi S; Naoi Y; Shimazu K; Shimoda M; Kagara N; Tanei T; Miyake T; Kim SJ; Noguchi S
    Breast Cancer Res Treat; 2019 Apr; 174(3):627-637. PubMed ID: 30607631
    [TBL] [Abstract][Full Text] [Related]  

  • 14. BRCA1-methylated sporadic breast cancers are BRCA-like in showing a basal phenotype and absence of ER expression.
    Bal A; Verma S; Joshi K; Singla A; Thakur R; Arora S; Singh G
    Virchows Arch; 2012 Sep; 461(3):305-12. PubMed ID: 22820987
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Genetic and epigenetic characterization of the BRCA1 gene in Brazilian women at-risk for hereditary breast cancer.
    Felicio PS; Melendez ME; Arantes LM; Kerr LM; Carraro DM; Grasel RS; Campacci N; Scapulatempo-Neto C; Fernandes GC; de Carvalho AC; Palmero EI
    Oncotarget; 2017 Jan; 8(2):2850-2862. PubMed ID: 27926510
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Single CpG hypermethylation, allele methylation errors, and decreased expression of multiple tumor suppressor genes in normal body cells of mutation-negative early-onset and high-risk breast cancer patients.
    Böck J; Appenzeller S; Haertle L; Schneider T; Gehrig A; Schröder J; Rost S; Wolf B; Bartram CR; Sutter C; Haaf T
    Int J Cancer; 2018 Sep; 143(6):1416-1425. PubMed ID: 29659014
    [TBL] [Abstract][Full Text] [Related]  

  • 17. BRCA1 Promoter Methylation and Expression - Associations with ER+, PR+ and HER2+ Subtypes of Breast Carcinoma.
    Kumar M; Sahu RK; Goyal A; Sharma S; Kaur N; Mehrotra R; Singh UR; Hedau S
    Asian Pac J Cancer Prev; 2017 Dec; 18(12):3293-3299. PubMed ID: 29286222
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Triple-negative breast cancer and PTEN (phosphatase and tensin homologue) loss are predictors of BRCA1 germline mutations in women with early-onset and familial breast cancer, but not in women with isolated late-onset breast cancer.
    Phuah SY; Looi LM; Hassan N; Rhodes A; Dean S; Taib NA; Yip CH; Teo SH
    Breast Cancer Res; 2012 Nov; 14(6):R142. PubMed ID: 23116406
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Levels of DNA Methylation Vary at CpG Sites across the BRCA1 Promoter, and Differ According to Triple Negative and "BRCA-Like" Status, in Both Blood and Tumour DNA.
    Daniels SL; Burghel GJ; Chambers P; Al-Baba S; Connley DD; Brock IW; Cramp HE; Dotsenko O; Wilks O; Wyld L; Cross SS; Cox A
    PLoS One; 2016; 11(7):e0160174. PubMed ID: 27463681
    [TBL] [Abstract][Full Text] [Related]  

  • 20. BRCA1 deficiency is a recurrent event in early-onset triple-negative breast cancer: a comprehensive analysis of germline mutations and somatic promoter methylation.
    Brianese RC; Nakamura KDM; Almeida FGDSR; Ramalho RF; Barros BDF; Ferreira ENE; Formiga MNDC; de Andrade VP; de Lima VCC; Carraro DM
    Breast Cancer Res Treat; 2018 Feb; 167(3):803-814. PubMed ID: 29116469
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.